{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:32:47Z","timestamp":1761856367574,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007352","name":"Staatssekretariat f\u00fcr Bildung, Forschung und Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011928","name":"Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001468","name":"Singapore Eye Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.esmoop.2022.100446","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T17:38:56Z","timestamp":1649785136000},"page":"100446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17\/16 study"],"prefix":"10.1016","volume":"7","author":[{"given":"M.","family":"Mark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rusakiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hayoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.L.","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Maconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Froesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Tarussio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kandalaft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tissot-Renaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Metaxas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2022.100446_bib1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100446_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40265-020-01374-0","article-title":"Lurbinectedin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.esmoop.2022.100446_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100446_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100446_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100446_bib6","first-page":"3218","article-title":"Identification of CD206 as a potential biomarker of cancer stem-like cells and therapeutic agent in liver cancer","volume":"18","author":"Fan","year":"2019","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100446_bib7","doi-asserted-by":"crossref","first-page":"1683347","DOI":"10.1080\/2162402X.2019.1683347","article-title":"The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia","volume":"9","author":"Xu","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.esmoop.2022.100446_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4049\/jimmunol.177.1.40","article-title":"Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells","volume":"177","author":"Kryczek","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.esmoop.2022.100446_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100446_bib10","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1158\/0008-5472.CAN-04-4037","article-title":"Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production","volume":"65","author":"Allavena","year":"2005","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100446_bib11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100446_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17\/16)","volume":"31","author":"Metaxas","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100446_bib13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2022.100446_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2022.100446_bib15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100446_bib16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ctrv.2015.10.006","article-title":"Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma","volume":"41","author":"Ceresoli","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2022.100446_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100446_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/sonc.2002.30232","article-title":"The role of gemcitabine in the treatment of malignant mesothelioma","volume":"29","author":"Kindler","year":"2002","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100446_bib19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20050930","article-title":"B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma","volume":"203","author":"Kryczek","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100446_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","article-title":"Macrophage regulation of tumor responses to anticancer therapies","volume":"23","author":"De Palma","year":"2013","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.esmoop.2022.100446_bib21","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100446_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1084\/jem.20150295","article-title":"The interaction of anticancer therapies with tumor-associated macrophages","volume":"212","author":"Mantovani","year":"2015","journal-title":"J\u00a0Exp Med"},{"issue":"13","key":"10.1016\/j.esmoop.2022.100446_bib23","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00018-016-2166-5","article-title":"Tumor-associated macrophages and anti-tumor therapies: complex links","volume":"73","author":"Belgiovine","year":"2016","journal-title":"Cell Mol Life Sci"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292200062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292200062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:45Z","timestamp":1761856065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292200062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S205970292200062X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100446","relation":{},"ISSN":["2059-7029"],"issn-type":[{"type":"print","value":"2059-7029"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17\/16 study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100446"}}